title: Community based parasitic screening and treatment of Sudanese refugees: application and assessment of Centers for Disease Control guidelines.
abstract: Centers for Disease Control guidelines for schistosomiasis and strongyloidiasis in Sudanese and Somali refugees are not widely implemented. Given limited prevalence data, we conducted a seroprevalence study of schistosomiasis, strongyloidiasis, and loiasis in Sudanese refugees across diverse ages. Sudanese refugees, ages 4-78, were recruited via community organizations. Half of the patients (86/172), were seropositive for schistosomiasis (46/171; 26.9%), strongyloidiasis (56/172; 33%), or both (16/171; 9.4%). No Loa loa infections were detected. Infection rates were similar in adults and children except that no schistosomiasis was detected in children < 4 years of age at the time of immigration to the United States. The high prevalence of schistosomiasis and strongyloidiasis in a community-based sample of Sudanese confirms the urgency for compliance with CDC refugee health guidelines. We detected no co-infection with Loa loa using the most sensitive serologic techniques, allowing use of ivermectin, the most effective treatment of strongyloidiasis.
authors.affiliation: San Diego State University Graduate School of Public Health, San Diego, California 92182, USA.
authors.forename: Stephanie K
authors.initials: SK
authors.lastname: Brodine
authors.forename: Anne
authors.initials: A
authors.lastname: Thomas
authors.forename: Robert
authors.initials: R
authors.lastname: Huang
authors.forename: Judith
authors.initials: J
authors.lastname: Harbertson
authors.forename: Sanjay
authors.initials: S
authors.lastname: Mehta
authors.forename: John
authors.initials: J
authors.lastname: Leake
authors.forename: Thomas
authors.initials: T
authors.lastname: Nutman
authors.forename: Kathleen
authors.initials: K
authors.lastname: Moser
authors.forename: Jamie
authors.initials: J
authors.lastname: Wolf
authors.forename: Roshan
authors.initials: R
authors.lastname: Ramanathan
authors.forename: Peter
authors.initials: P
authors.lastname: Burbelo
authors.forename: John
authors.initials: J
authors.lastname: Nou
authors.forename: Patricia
authors.initials: P
authors.lastname: Wilkins
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Reed
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015766:Albendazole / Q000191:economics / Q000627:therapeutic use; D000871:Anthelmintics / Q000191:economics / Q000627:therapeutic use; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006373:Helminthiasis / Q000175:diagnosis* / Q000188:drug therapy* / Q000208:ethnology; D006801:Humans; D007559:Ivermectin / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012036:Refugees; D016036:Seroepidemiologic Studies; D013397:Sudan / Q000208:ethnology; D014481:United States; D055815:Young Adult
chemical_list: D000871:Anthelmintics; D007559:Ivermectin; D015766:Albendazole